Lumateperone

• Description :

  Lumateperone (ITI-007) is an orally active 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone has anticancer activity and can also be used for the study of schizophrenia and bipolar depression[1][2][3].

• Product Name Alternative :

  ITI-007

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  5-HT Receptor; Dopamine Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Cancer; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/lumateperone.html

• Purity :

  99.83

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CN1C2=C3C([C@@]4([H])[C@@](CCN(C4)CCCC(C5=CC=C(C=C5)F)=O)([H])N3CC1)=CC=C2

• Molecular Formula :

  C24H28FN3O

• Molecular Weight :

  393.50

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Lumateperone|[2]Jinyuan Zhang, et al. Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth. Mol Inform. 2022 Mar 30:e2200011.|[3]J Titulaer, et al. Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism. Eur Neuropsychopharmacol. 2022 Jul 22;62:22-35.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  5-HT2 Receptor; D1 Receptor; D2 Receptor

• CAS Number :

  [313368-91-1]